Published in Women's Health Weekly, May 15th, 2003
MCG is taking part in an international study that adds interferon gamma 1-b to the standard treatment protocol for women with late-stage ovarian cancer, said Dr. Sharad Ghamande, a principal investigator. Dr. Michael S. Macfee, chief of the MCG section of gynecologic oncology, is a sub-investigator on the study.
Experience with interferon gamma 1-b in laboratory studies and previous clinical trials indicates that the drug may...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly